Lemborexant as a Potential Risk Factor for Sleep-Related Bruxism in a Patient with Complex Post-traumatic Stress Disorder: A Case Report

This article describes a case involving a 21-year-old woman with complex post-traumatic stress disorder (C-PTSD) who developed sleep-related bruxism (SB) following the use of the dual orexin receptor antagonist, lemborexant, for insomnia. Lemborexant was initially prescribed at 5 mg/day, and the patient experienced enuresis and SB after discharge-related anxiety. Reducing the dosage to 2.5 mg/day led to a rapid improvement in SB without recurrence over a 8-week follow-up period. This case highlights the potential risk of SB associated with lemborexant use, especially in patients with C-PTSD. Further, it demonstrates the importance of considering adverse events when selecting medication strategies for PTSD.